Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...

The trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach ...

Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat ...

(a) Axial T2-weighted fat sat image and (b) corresponding axial T1-weighted fat sat contrast-enhanced image of a patient with pancreatic adenocarcinoma are shown. Note the presence of small ...

Cancer is one of the most formidable health challenges of our time, affecting nearly half of us during our lives. While treatments have significantly improved in recent decades, the biggest challenge ...

MCCLEAN, VA, UNITED STATES, December 16, 2024 /EINPresswire / -- Perthera, the leader in AI-driven Precision Oncology Decision Support, has unveile ...

Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of ...

Medical announced that an abstract entitled “Interim analysis of feasibility, safety, and tumor control in two first-in-human ...

Actuate Therapeutics (ACTU) announced data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with ...